TXP1 Brain Shuttle Platform
Enabling technology for CNS biologics delivery
Pre-clinicalActive
Key Facts
Indication
Enabling technology for CNS biologics delivery
Phase
Pre-clinical
Status
Active
Company
About Ossianix
Ossianix is a private biotech leveraging a unique shark-derived VNAR antibody platform to overcome the significant challenge of delivering biologics across the blood-brain barrier. Its lead asset, the TXP1 Brain Shuttle, targets the transferrin receptor 1 (TfR1) to facilitate receptor-mediated transcytosis, demonstrating >40-fold enhanced brain delivery in primates with favorable specificity and pharmacokinetics. The company, founded by industry veterans and backed by strategic investors, is positioned to enable a new generation of CNS therapies through partnerships and internal pipeline development, though it faces competition and the inherent risks of pioneering a novel delivery modality.
View full company profile